Welcome to our dedicated page for LakeShore Biopharma Co. news (Ticker: LSBCF), a resource for investors and traders seeking the latest updates and insights on LakeShore Biopharma Co. stock.
LakeShore Biopharma Co., Ltd (LSBCF), previously known as YS Biopharma, is described as a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. This news page aggregates company announcements and market updates related to LSBCF, giving investors and observers a single place to review its disclosed developments.
Recent news has highlighted two major themes for LakeShore Biopharma: changes in its trading venue and a planned going‑private transaction. The company announced that its ordinary shares and warrants were suspended from trading on The Nasdaq Capital Market after a delisting determination related to minimum bid price requirements and prior reverse stock split history. On the same day, it reported that its ordinary shares and warrants were expected to begin trading on the OTC Pink Open Market under the symbols LSBCF and LSBWF, while stating that this transition did not change its underlying business operations and that it remained a reporting company with the U.S. Securities and Exchange Commission.
In a separate announcement, LakeShore Biopharma disclosed that it entered into a definitive Agreement and Plan of Merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. The transaction is structured as a going‑private merger in which the company would become a wholly owned subsidiary of Oceanpine Skyline Inc., with cash consideration per ordinary share for shareholders other than specified excluded and dissenting shares. If completed, the merger would result in the company becoming privately held and its shares no longer being quoted on the OTC Pink Open Market.
Visitors to this page can review such corporate actions, capital markets updates, and other official press releases from LakeShore Biopharma in one place, making it easier to follow how the company describes its strategic and regulatory milestones over time.
LakeShore Biopharma (OTCPK: LSBCF) disclosed that its special committee received a revised preliminary non-binding proposal dated March 24, 2026 from Oceanpine Skyline and Oceanpine Merger Sub to acquire remaining ordinary shares at US$0.06 per share.
The Special Committee will evaluate the Proposed Transaction with financial and legal advisors. The company cautioned that no decision has been made, no assurance a definitive offer will be made, and it is not obligated to provide updates except as required by law.
LakeShore Biopharma (OTCPK: LSBCF / LSBWF) announced receipt of a February 4, 2026 notice from the Buyer Group concerning the previously agreed going-private Merger Agreement at $0.90 per share.
The Buyer Group asserted that arbitral awards and a resulting liability of approximately RMB576,500,000 constitute a Company Material Adverse Effect, and indicated it will not vote at the postponed EGM originally scheduled for February 12, 2026. The Buyer Group stated willingness to negotiate amendments; the company will evaluate options and provide further updates as required under applicable law.
LakeShore Biopharma (OTCPK: LSBCF / LSBWF) has called an extraordinary general meeting of shareholders for February 12, 2026 at 11:00 a.m. Beijing time to vote on a previously announced Agreement and Plan of Merger dated November 4, 2025 with Oceanpine Skyline Inc. If approved, Merger Sub will merge into LakeShore and the company will become a wholly owned subsidiary of Parent and a privately held company.
Upon closing, the company’s ordinary shares and warrants will no longer be quoted on any public marketplace (including OTC Pink) and will cease to be registered under Section 12 of the Securities Exchange Act. Shareholders of record as of 5:00 p.m. Cayman Islands time on January 16, 2026 may vote. Relevant filings include the Schedule 13E-3 and definitive proxy statement filed with the SEC.
LakeShore Biopharma (Nasdaq:LSB) announced that effective September 22, 2025 its ordinary shares and warrants were suspended from trading on Nasdaq and are expected to begin trading on the OTC Pink Open Market under symbols LSBCF (shares) and LSBWF (warrants).
The Nasdaq action follows a delisting determination dated September 11, 2025 due to non-compliance with the minimum bid price rule and ineligibility for a compliance period because of a prior reverse stock split. The company said the transition does not change business operations and that it remains a reporting company with the SEC.
LakeShore Biopharma (OTCPK: LSBCF / LSBWF) entered into a definitive Agreement and Plan of Merger with Oceanpine Skyline Inc. and its Merger Sub to become a privately held company in a transaction implying an equity value of approximately US$37 million. At the effective time each outstanding ordinary share (other than excluded/dissenting shares) will be cancelled for US$0.90 per share in cash. The consideration reflects a ~15.4% premium to the closing price on August 15, 2025. The deal is expected to close in Q1 2026, is subject to customary closing conditions and a shareholder vote requiring at least a two-thirds approval, and would remove the company’s shares from the OTC Pink Open Market.
The transaction is funded by an equity commitment and a rollover by certain shareholders who represent ~53.35% of voting rights.
LakeShore Biopharma (Nasdaq: LSB) announced its transition from Nasdaq to the OTC Pink Open Market effective September 22, 2025. The company's ordinary shares and warrants will trade under the new symbols "LSBCF" and "LSBWF" respectively.
The delisting from Nasdaq follows a determination letter received on September 11, 2025, citing non-compliance with the minimum bid price requirement and ineligibility for a compliance period due to a previous reverse stock split. Despite the market transition, LakeShore Biopharma maintains its SEC reporting status and business operations remain unchanged.